Cancer drug’s ‘impressive responses’ hailed by haematologist

An ASX-listed oncology company’s first-in-class cancer drug has shown encouraging clinical activity in a difficult-to-treat patient population, as per newly released results from an ongoing study.

An ASX-listed oncology company’s first-in-class cancer drug has shown encouraging clinical activity in a difficult-to-treat patient population, as per newly released results from an ongoing study.

Led by renowned haematologist Professor H. Miles Prince at Epworth hospital in Melbourne, the study on a Phase 1b expansion cohort is designed to evaluate safety and look at the effects of PTX-100 on relapsed and refractory T-cell lymphomas (TCL).

“We continue to see impressive responses in both systemic and cutaneous T cell lymphomas on this study,” Professor Prince said.

“Furthermore, PTX-100 continues to be extremely well tolerated by patients. We look forward to continuing accruing patients to the trial who otherwise have limited treatment options.”

After recently being granted Orphan Drug Designation by the FDA, one of PTX-100’s targets is an area of high unmet need – a blood cancer known as peripheral T-cell lymphoma (PTCL).

Prescient Therapeutics Limited (ASX: PTX) said PTX-100 continues to exhibit an excellent safety profile, even at its new highest dose of 2,000mg/m2, as well as a striking response in a patient with refractory cutaneous TCL (CTCL).

Prescient CEO and MD Steven Yatomi-Clarke noted it was “very exciting to see PTX-100 show clinical activity in a patient population that is notoriously difficult to treat, and where these patients have failed several lines of prior therapies”.

He added that the drug’s excellent safety profile was “uncharacteristic of available TCL therapies”.

“It is exciting to see encouraging responses in CTCL patients, alongside PTCL patients, and we will aim to recruit more CTCL patients to the study. We look forward to sharing these updates with the market.”

Source: PTX

Currently available therapies for PTCL are typically characterised by high occurrence of serious toxicities; low response rates (<30%) and short duration of responses (3-4 months).

There are more than 5,600 cases per year in the US. A common therapy currently used is Folotyn, which costs more than US$450,000 per year, per patient, and comes with a greater than 75% chance of serious adverse side effects.

Join Prescient CEO and MD Steven Yatomi-Clarke for an investor briefing next Wednesday, 2nd November at 12pm (AEDT), where he will discuss these results in more detail and provide a company update. Click here to book in.

Reach Markets has been engaged by Prescient Therapeutics Limited to assist with their investor communications and may receive fees for its services.

Past performance is not a reliable indicator of future performance.

Sources:

This Week’s News

News

22 November 2023

Rare Earths Industry Review: Part 2

News

22 November 2023

Rare Earths Industry Review

News

22 November 2023

World first left ventricle heart failure device gears up for approval

General Advice Warning

Any advice provided by Reach Markets including on its website and by its representatives is general advice only and does not consider your objectives, financial situation or needs, and you should consider whether it is appropriate for you. This might mean that you need to seek personal advice from a representative authorised to provide personal advice. If you are thinking about acquiring a financial product, you should consider our Financial Services Guide (FSG)

including the Privacy Statement and any relevant Product Disclosure Statement or Prospectus (if one is available) to understand the features, risks and returns associated with the investment.

Please click here to read our full warning.